Patel Raj H, Parikh Charmy, Upadhyay Henil, Sonaiya Sneh, Ramnath Parameswaran, Singh Shubham, Patel Umang, Kothari Truptesh
Internal Medicine, St. Mary Medical Center, Langhorne, USA.
Internal Medicine, Mercy Catholic Medical Center, Philadelphia, USA.
Cureus. 2024 Nov 29;16(11):e74772. doi: 10.7759/cureus.74772. eCollection 2024 Nov.
Resmetirom is a thyroid hormone receptor agonist that has been recently approved by the FDA for the management of metabolic dysfunction-associated steatohepatitis (MASH). MASH is a severe form of metabolic dysfunction-associated fatty liver disease (MASLD), which is marked by hepatic inflammation and potential progression to cirrhosis and liver cancer. This review analyzes and demonstrates the efficacy of resmetirom in reducing intra-hepatic lipids, improving liver histology, and improving metabolic parameters. Key outcomes of this study indicate that resmetirom leads to non-alcoholic steatohepatitis (NASH) resolution and fibrosis improvement in a substantial percentage of patients. Although this drug has common gastrointestinal side effects, it maintains a favorable safety profile. With the increase in demand for treatments of MASH, the ongoing phase 3 trials will provide critical insights into the long-term efficacy and safety profile of resmetirom and further solidify its potential as a groundbreaking therapeutic option for the management of MASH.
瑞美替隆是一种甲状腺激素受体激动剂，最近已获得美国食品药品监督管理局（FDA）批准，用于治疗代谢功能障碍相关脂肪性肝炎（MASH）。MASH是代谢功能障碍相关脂肪性肝病（MASLD）的一种严重形式，其特征是肝脏炎症，并有可能进展为肝硬化和肝癌。本综述分析并证明了瑞美替隆在降低肝内脂质、改善肝脏组织学以及改善代谢参数方面的疗效。本研究的主要结果表明，瑞美替隆可使相当比例的患者非酒精性脂肪性肝炎（NASH）得到缓解，纤维化得到改善。尽管该药物有常见的胃肠道副作用，但其安全性良好。随着对MASH治疗需求的增加，正在进行的3期试验将为瑞美替隆的长期疗效和安全性提供关键见解，并进一步巩固其作为治疗MASH的突破性治疗选择的潜力。
